Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23,000 UNIT/23 ML SUBCUT SOLN (OTHER RX-201599) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved July 2, 2026 , from http://ppman.hank.ai/transparency/procedure/RX-201599/by-state?code_type=OTHER
“OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23,000 UNIT/23 ML SUBCUT SOLN (OTHER RX-201599) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/RX-201599/by-state?code_type=OTHER. Accessed
July 2, 2026 .
“OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23,000 UNIT/23 ML SUBCUT SOLN (OTHER RX-201599) by State,” HANK Price Transparency ,
accessed July 2, 2026 ,
http://ppman.hank.ai/transparency/procedure/RX-201599/by-state?code_type=OTHER.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
OTHER · across United States
RX-201599 — Ocrelizumab 920 Mg-hyaluronidase-ocsq 23,000 Unit/23 Ml Subcut Soln
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$91,646
National median
$59,421 – $94,742
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for RX-201599 (OTHER), with interquartile range
State Median p25 p75
DE $91,646 $59,421 $94,742